CIK: 0002013341
Total reported value
$460.3M
Reporting period: 2026-03-31 · Number of holdings: 17
Foresite Capital Management VI LLC disclosed 17 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $460.3M and a quarterly turnover rate of 76.8%.
Browse other institutions with $100M to $1B AUMBrowse other institutions starting with "F"
Sector classification currently covers about 0% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Add ALMS
0.0% $52.1M
Add CGON
0.0% $58.1M
Trim VSTM
+0.4% -$7.5M
Add CRVS
+32.6% $16.2M
Add 260
0.0% $20.1M
Trim KYMR
0.0% $801.9K
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | CGON | Cg Oncology INC | Stock-Other | 32.67% | +4.79% | — | |
| 2 | ALMS | Alumis INC | Stock-Other | 20.33% | +7.80% | — | |
| 3 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 11.77% | +1.46% | — | |
| 4 | CRVS | Corvus Pharmaceuticals INC | Stock-Other | 5.82% | +2.61% | +32.58% | |
| 5 | DNLI | Denali Therapeutics INC | Stock-Other | 5.05% | +0.06% | +21.00% | |
| 6 | AGIO | Agios Pharmaceuticals INC | Stock-Other | 3.86% | -0.50% | -0.94% | |
| 7 | VSTM | Verastem INC | Stock-Other | 3.62% | -3.70% | +0.37% | |
| 8 | KYMR | Kymera Therapeutics INC | Stock-Other | 2.65% | -0.79% | — | |
| 9 | NERV | Minerva Neurosciences INC | Stock-Other | 2.60% | +2.60% | NEW | |
| 10 | CLDX | Celldex Therapeutics INC | Stock-Other | 2.18% | +2.18% | NEW | |
| 11 | ATAI | Ataibeckley INC | Stock-Other | 2.12% | +2.12% | NEW | |
| 12 | HNGE | Hinge Health Inc-a | Stock-Other | 1.85% | -0.05% | +63.26% | |
| 13 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 1.67% | +1.67% | NEW | |
| 14 | OKUR | Onkure Therapeutics Inc-a | Stock-Other | 1.30% | +1.30% | NEW | |
| 15 | JBIO | Jade Biosciences INC | Stock-Other | 0.98% | +0.98% | NEW | |
| 16 | GHRS | GH Research PLC | Stock-Other | 0.96% | +0.96% | NEW | |
| 17 | ✓ | Zura Bio LTD | Stock-Other | 0.58% | +0.58% | NEW |
Performance for Q3 2026
+16%
Performance Last 4 Quarters
+216%
Based on 79% of reported portfolio value with available pricing
Not enough sector-mapped data yet
Foresite Capital Management VI LLC's most significant position changes for 2026-03-31: Sold out: Rapt Therapeutics INC (RAPT); Sold out: Natera INC (NTRA); New buy: Minerva Neurosciences INC (NERV); Sold out: AtaiBeckley Inc. (ATAI); New buy: Celldex Therapeutics INC (CLDX).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ALMS | Alumis INC | +7.8% | — | Unchanged |
| 2 | CGON | Cg Oncology INC | +4.8% | — | Unchanged |
| 3 | CRVS | Corvus Pharmaceuticals INC | +2.6% | +32.58% | Add |
| 4 | 260 | Centessa Pharmaceuticals-adr | +1.5% | — | Unchanged |
| 5 | DNLI | Denali Therapeutics INC | +0.1% | +21.00% | Add |
| 6 | HNGE | Hinge Health Inc-a | -0.1% | +63.26% | Add |
| 7 | AGIO | Agios Pharmaceuticals INC | -0.5% | -0.94% | Trim |
| 8 | KYMR | Kymera Therapeutics INC | -0.8% | — | Unchanged |
| 9 | VSTM | Verastem INC | -3.7% | +0.37% | Add |
| 10 | RAPT | Rapt Therapeutics INC | — | EXIT | Sold out |
| 11 | NTRA | Natera INC | — | EXIT | Sold out |
| 12 | NERV | Minerva Neurosciences INC | — | NEW | New buy |
| 13 | ATAI | AtaiBeckley Inc. | — | EXIT | Sold out |
| 14 | CLDX | Celldex Therapeutics INC | — | NEW | New buy |
| 15 | ATAI | Ataibeckley INC | — | NEW | New buy |
| 16 | CRNX | Crinetics Pharmaceuticals In | — | NEW | New buy |
| 17 | OKUR | Onkure Therapeutics Inc-a | — | NEW | New buy |
| 18 | JBIO | Jade Biosciences INC | — | NEW | New buy |
| 19 | GHRS | GH Research PLC | — | NEW | New buy |
| 20 | ✓ | Zura Bio LTD | — | NEW | New buy |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026-03-31 | 2026-05-15 | 13F-HR | View on EDGAR |
| 2025-12-31 | 2026-02-17 | 13F-HR | View on EDGAR |
| 2025-09-30 | 2025-11-14 | 13F-HR | View on EDGAR |
| 2025-06-30 | 2025-08-12 | 13F-HR | View on EDGAR |
| 2025-03-31 | 2025-05-15 | 13F-HR | View on EDGAR |
| 2024-12-31 | 2025-02-14 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0001534843
Total reported value
$460.3M
244 stks
2022-09-30
Stale — no recent filing
AUM within 0.0% of this institution
CIK 0002011821
Total reported value
$460.2M
199 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001505246
Total reported value
$460.1M
165 stks
2020-09-30
Stale — no recent filing
AUM within 0.0% of this institution
Institutions with overlapping top holdings
CIK 0001792206
Total reported value
$271.0M
9 stks
2026-03-31
2 of the top 5 holdings overlap, including Alumis INC
CIK 0001839948
Total reported value
$3.5B
49 stks
2026-03-31
2 of the top 5 holdings overlap, including Cg Oncology INC
CIK 0001193586
Total reported value
$260.3M
3 stks
2026-03-31
1 of the top 5 holdings overlap, including Corvus Pharmaceuticals INC